Leadership Overview
InnoCare Pharma has 4 executives leading key functions including strategy, finance, medical affairs, and operations.
Driven by scientific innovation, InnoCare Pharma is dedicated to developing first-in-class or best-in-class therapies for global markets, addressing significant unmet clinical needs in oncology and autoimmune diseases.
Driven by scientific innovation, InnoCare Pharma is dedicated to developing first-in-class or best-in-class therapies for global markets, addressing significant unmet clinical needs in oncology and autoimmune diseases.
Leadership Roles at InnoCare Pharma
Nghia Ba - Chief Executive Officer
Nghia Ba, the Chief Executive Officer at InnoCare Pharma, directs the overarching corporate strategy and operational execution. This leadership role involves guiding the company's mission to develop innovative drugs for malignant tumors and autoimmune diseases, ensuring alignment with global market demands. Ba oversees the integration of research and commercialization capabilities, fostering an environment where scientific discovery translates into patient benefit. The Chief Executive Officer's focus remains on advancing the pipeline and securing InnoCare Pharma's position as a leader in delivering high-quality, innovative medicines worldwide. Nghia Ba drives the company's commitment to addressing significant unmet clinical needs through pioneering therapeutic solutions.
Xin Fu - Chief Financial Officer
Xin Fu, the Chief Financial Officer at InnoCare Pharma, manages all financial operations and strategic financial planning. This executive oversees capital allocation, investor relations, and the financial health of the organization, ensuring resources are effectively deployed to support drug development and commercialization efforts. Fu's responsibilities include maintaining robust financial controls and driving fiscal discipline across all departments. The Chief Financial Officer plays a critical part in evaluating investment opportunities and managing the company's financial performance to support its growth objectives in the pharmaceutical sector. Xin Fu ensures the financial stability required for InnoCare Pharma to pursue its mission of creating first-in-class or best-in-class therapies for global patients.
Qiang Zhou - Chief Medical Officer
Qiang Zhou, the Chief Medical Officer at InnoCare Pharma, leads the clinical development and medical affairs strategy. This role is central to advancing the company's pipeline in hematological malignancies, autoimmune diseases, and solid tumors, ensuring that therapeutic candidates meet rigorous clinical standards. Zhou oversees the design and execution of clinical trials, guiding the transition of innovative drug candidates from research to regulatory submission. The Chief Medical Officer's expertise is crucial for identifying and prioritizing significant unmet clinical needs, driving the development of therapies that offer substantial patient benefits. Qiang Zhou ensures InnoCare Pharma's commitment to delivering high-quality, innovative medicines is realized through sound medical and scientific leadership.
Kevin Gao - Chief Operations Officer
Kevin Gao, the Chief Operations Officer at InnoCare Pharma, directs the company's operational infrastructure and execution. This leadership position involves optimizing manufacturing processes, supply chain management, and ensuring the efficient delivery of pharmaceutical products to global markets. Gao oversees the integration of research and commercialization capabilities, translating scientific innovation into tangible patient access. The Chief Operations Officer's focus is on enhancing operational efficiency and scalability to support InnoCare Pharma's ambitious development goals. Kevin Gao ensures that the company's comprehensive capabilities are leveraged effectively to create and deliver best-in-class therapies, reinforcing the commitment to addressing unmet clinical needs worldwide.
Explore Leadership Teams in Manufacturing
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is dedicated to addressing unmet patient needs by advancing scientific research, expanding access to quality medicines, and streamlining the delivery of treatments -from established generics to cutting-edge therapeutic solutions.
Company Leadership CS
HL
AJ
CO
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
Integrace Health is a therapy-focused healthcare company based in India, specializing in innovative solutions for Musculoskeletal Disorders, Pain Management, and Women's Health. Founded in 2018, it has quickly risen to become one of India's top 70 pharmaceutical companies, with five brands ranked #1 in their respective therapy areas. The company aims to significantly impact the health and well-being of the Indian population and envisions becoming a transformative force in the healthcare landscape by 2030. Integrace Health is committed to innovation, disciplined execution, and inspiring collaboration among its stakeholders.
Company Leadership KR
SS
AA
AN
Founded in 2004, Corona Remedies is headquartered in Thaltej, Gujarat. They are a pharmaceutical manufacturing company.
Company Leadership BS
ST
Frequently Asked Questions Regarding InnoCare Pharma Top Executives and Leadership Team
